[A19-73] Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2019
Commission awarded on 29.08.2019 by the Federal Joint Committee (G-BA).
Adults with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of ≥ 400 ng/mL and who have been previously treated with sorafenib
Negative effects in some side effects do not call into question the major advantage in overall survival; overall proof of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-13||Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A20-03||Ramucirumab (hepatocellular carcinoma) - Addendum to Commission A19-73||Commission completed|
|G15-02||Ramucirumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)||Commission completed|
|A16-23||Ramucirumab - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A16-11||Ramucirumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A16-10||Ramucirumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A16-50||Ramucirumab (colorectal cancer) - Addendum to Commission A16-10||Commission completed|